As shown in Figure 1A, a significant increase in soluble ACE2 levels was observed in both non-severe and severe COVID-19 patients, compared to the healthy subjects (P < 0.001 and P < 0.0001, respectively). This evidence concerns the gene ACE2 and COVID-19.